Terms: = Prostate cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
413 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Regulation of Molecular Biomarkers Associated with the Progression of prostate cancer.
Martin-Caraballo M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673756
[TBL] [Abstract] [Full Text] [Related]
3. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
4. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
Cheng B; Li L; Luo T; Wang Q; Luo Y; Bai S; Li K; Lai Y; Huang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):67. PubMed ID: 38429845
[TBL] [Abstract] [Full Text] [Related]
5. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
6. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptional Inflammatory Signature in Healthy Donors and Different Radiotherapy cancer Patients.
O'Brien G; Kamuda M; Cruz-Garcia L; Polozova M; Tichy A; Markova M; Sirak I; Zahradnicek O; Widłak P; Ponge L; Polanska J; Badie C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256152
[TBL] [Abstract] [Full Text] [Related]
8. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract] [Full Text] [Related]
9. treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
10. Mechanism of Antitumor Effects of Saffron in Human prostate cancer Cells.
Khan M; Hearn K; Parry C; Rasid M; Brim H; Ashktorab H; Kwabi-Addo B
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201944
[TBL] [Abstract] [Full Text] [Related]
11. Mechanism-centric regulatory network identifies NME2 and myc programs as markers of Enzalutamide resistance in CRPC.
Panja S; Truica MI; Yu CY; Saggurthi V; Craige MW; Whitehead K; Tuiche MV; Al-Saadi A; Vyas R; Ganesan S; Gohel S; Coffman F; Parrott JS; Quan S; Jha S; Kim I; Schaeffer E; Kothari V; Abdulkadir SA; Mitrofanova A
Nat Commun; 2024 Jan; 15(1):352. PubMed ID: 38191557
[TBL] [Abstract] [Full Text] [Related]
12. Targeted anti-tumor synergistic effects of myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells.
Ghorbani R; Gharbavi M; Sharafi A; Rismani E; Rezaeejam H; Mortazavi Y; Johari B
Oncol Res; 2023; 32(1):101-125. PubMed ID: 38188680
[TBL] [Abstract] [Full Text] [Related]
13. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
14. The Molecular, Immunologic, and Clinicodemographic Landscape of myc-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
15. Drastic Synergy of Lovastatin and
Yao CJ; Chang CL; Hu MH; Liao CH; Lai GM; Chiou TJ; Ho HL; Kuo HC; Yang YY; Whang-Peng J; Chuang SE
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960146
[TBL] [Abstract] [Full Text] [Related]
16. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.
Chen Z; Yang X; Chen Z; Li M; Wang W; Yang R; Wang Z; Ma Y; Xu Y; Ao S; Liang L; Cai C; Wang C; Deng T; Gu D; Zhou H; Zeng G
BMC Med; 2023 Oct; 21(1):402. PubMed ID: 37880708
[TBL] [Abstract] [Full Text] [Related]
17. myc is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
Crowell PD; Giafaglione JM; Jones AE; Nunley NM; Hashimoto T; Delcourt AML; Petcherski A; Agrawal R; Bernard MJ; Diaz JA; Heering KY; Huang RR; Low JY; Matulionis N; Navone NM; Ye H; Zoubeidi A; Christofk HR; Rettig MB; Reiter RE; Haffner MC; Boutros PC; Shirihai OS; Divakaruni AS; Goldstein AS
Cell Rep; 2023 Oct; 42(10):113221. PubMed ID: 37815914
[TBL] [Abstract] [Full Text] [Related]
18. The role of NFATc1 in the progression and metastasis of prostate cancer: A review on the molecular mechanisms and signaling pathways.
Hasani S; Fathabadi F; Saeidi S; Mohajernoei P; Hesari Z
Cell Biol Int; 2023 Dec; 47(12):1895-1904. PubMed ID: 37814550
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract] [Full Text] [Related]
20. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract] [Full Text] [Related]
[Next]
